Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

SELLAS Life Sciences Group, Inc. Director's Dealing 2014

Jan 23, 2014

33651_dirs_2014-01-22_0b2427c8-00e1-49fe-a7e2-38d3d5e349b6.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Galena Biopharma, Inc. (GALE)
CIK: 0001390478
Period of Report: 2014-01-17

Reporting Person: Hillsberg Sanford (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2014-01-17 Common Stock S 200000 $6.925 Disposed 110447 Indirect

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 17974 Direct